Role of glycogen synthase kinase-3 in l-DOPA-induced neurotoxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 11, 2009, Pages 1359-1368

  Koh, Seong Ho ^a   Kim, Seung Hyun ^a   Kim, Hee Tae ^a  

^a Hanyang University   (South Korea)

Author keywords

Glycogen synthase kinase 3; Inhibitor; L DOPA; Neurotoxicity

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GENOMIC DNA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; ISRADIPINE; LEVODOPA; LITHIUM CHLORIDE; MONOAMINE OXIDASE INHIBITOR; QUINONE DERIVATIVE; SEMIQUINONE;

APOPTOSIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOARCHITECTURE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG OXIDATION; DYSKINESIA; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HYPERTENSION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; STROKE;

ANIMALS; ANTIPARKINSON AGENTS; CELL DEATH; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEVODOPA; NEURONS; NEUROTOXICITY SYNDROMES;

EID: 70449127681     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903170663     Document Type: Review

References (89)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681
2. Cotzias GC, Van Woert MH, et al. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379
3. Fehling C. Treatment of Parkinson's syndrome with l-dopa. A double blind study. Acta Neurol Scand 1966;42:367-372
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458
5. Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA. Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 2009;159:925-935
6. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003;5:165-176
7. Chen J, Wersinger C, Sidhu A. Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem 2003;278:28089-28100
8. Soliman MK, Mazzio E, Soliman KF. levoDOPA modulating effects of inducible nitric oxide synthase and reactive oxygen species in glioma cells. life Sci 2002;72:185-198
9. Boje KM. Nitric oxide neurotoxicity in neurodegenerative diseases. Front Biosci 2004;9:763-776
10. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levoDOPA on catecholamine-rich neurons. Mov Disord 1992;7:23-31
11. Mena MA, Pardo B, Paino Cl, et al. levoDOPA toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440
12. Steece-Collier K, Collier TJ, Sladek CD, et al. Chronic levoDOPA impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208
13. Tanaka M, Sotomatsu A, Kanai H, et al. DOPA and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203
14. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by l-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464
15. Maharaj H, Sukhdev Maharaj D, Scheepers M, et al. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063:180-186
16. Muller T, Hefter H, Hueber R, et al. Is levoDOPA toxic? J Neurol 2004;251(Suppl 6):44-46
17. Agil A, Duran R, Barrero F, et al. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa. J Neurol Sci 2006;240:31-36
18. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of l-DOPA on mesencephalic cell cultures. J Neurochem 1993;61:1470-1478
19. Kondo T. levoDOPA therapy from the neuroprotection viewpoint. From a clinical outlook. J Neurol 2005;252:IV32-36
20. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-527
21. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102
22. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 2000;75:2401-2408
23. Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 2001;276:37436-37442
24. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65:391-426
25. Koh SH, Kim SH, Kwon H, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 2003;118:72-81
26. Koh SH, Kim SH, Kwon H, et al. Phosphatidylinositol-3 kinase/Akt and GSK-3 mediated cytoprotective effect of epigallocatechin gallate on oxidative stress-injured neuronal-differentiated N18D3 cells. Neurotoxicology 2004;25:793-802
27. Takadera T, Ohyashiki T. Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons. Eur J Pharmacol 2004;499:239-245 (Pubitemid 39233662)
28. Watcharasit P, Bijur GN, Song l, et al. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 2003;278:48872-48879
29. Chen G, Bower KA, Ma C, et al. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004;18:1162-1164
30. Koh SH, Song C, Noh MY, et al. Inhibition of glycogen synthase kinase-3 reduces l-DOPA-induced neurotoxicity. Toxicology 2008;247:112-118
31. Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007;27:8138-8148
32. Chen l, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008;287:425-433
33. Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci 1989;12:415-461
34. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996;67:443-462
35. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004;56:331-349
36. Conway KA, Rochet JC, Bieganski RM, lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-1349
37. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006;313:324-328
38. Chen l, Cagniard B, Mathews T, et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005;280:21418-21426
39. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259 (Pubitemid 36131051)
40. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003;278:43628-43635
41. laVoie MJ, Ostaszewski Bl, Weihofen A, et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005;11:1214-1221
42. Norris EH, Giasson BI, Hodara R, et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 2005;280:21212-21219
43. Mazzulli JR, Mishizen AJ, Giasson BI, et al. Cytosolic catechols inhibit ?-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 2006;26:10068-10078
44. Duka T, Rusnak M, Drolet RE, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 2006;20:2302-2312
45. Goers J, Manning-Bog AB, McCormack Al, et al. Nuclear localization of alpha-synuclein and its interactionwith histones. Biochemistry 2003;42:8465-8471
46. Duka T, Duka V, Joyce JN, Sidhu A. {alpha}-Synuclein contributes to GSK-3{beta}-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009. In press
47. Mosharov EV, larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and a-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62:218-229
48. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-788
49. Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAl, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008;115:193-203
50. Olanow CW, Gauger ll, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559
51. Fahn S, and the Parkinson study group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37-42
52. Chan Pl, Nutt JG, Holford NH. levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation. Pharm Res 2007;24:791-802
53. Kang UJ, lee WY, Chang JW. Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models. Hum Cell 2001;14:39-48
54. liste I, Navarro B, Johansen J, et al. low-level tyrosine hydroxylase (TH) expression allows for the generation of stable TH+ cell lines of human neural stem cells. Hum Gene Ther 2004;15:13-20
55. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086
56. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. lancet Neurol 2007;6:933-938
57. Hald A, lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005;193:279-290
58. Grunblatt E, Mandel S, Youdim MB. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann NY Acad Sci 2000;899:262-273 (Pubitemid 30352792)
59. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989;86:1398-1400
60. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:242-250
61. Miyazaki I, Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 2008;62:141-150
62. Hawley MD, Tatawawadi SV, Piekarski S, et al. Electrochemical studies of the oxidation pathways of catecholamines. J Am Chem Soc 1967;89:447-450
63. Baez S, linderson Y, Segura-Aguilar J. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem Mol Med 1995;54:12-18
64. Segura-Aguilar J, Metodiewa D, Welch CJ. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1998;1381:1-6
65. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev 2007;59:125-150
66. Bialecka M, Drozdzik M, Klodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levoDOPA therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004;110:260-266
67. Przedborski S, Jackson-lewis V, Muthane U, et al. Chronic levoDOPA administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
68. Spencer JP, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by l-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS lett 1994;353:246-250
69. Wick MM. levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol 1989;92:329S-31S
70. Nyholm D, lennernas H, Gomes-Trolin C, et al. levoDOPA pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96
71. Woodgett cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 1991;200:564-577
72. Koh SH, lee YB, Kim KS, et al. Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. Eur J Neurosci 2005;22:301-309
73. Koh SH, Roh H, lee SM, et al. Phosphatidylinositol 3-kinase activator reduces motor neuronal cell death induced by G93A or A4V mutant SOD1 gene. Toxicology 2005;213:45-55
74. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932
75. Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway. Mol Cell Biol 2002;22:578-586
76. Cantley lC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657
77. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998;329(Pt 2):209-223
78. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci 2002;115:3977-3978
79. Kirschenbaum F, Hsu SC, Cordell B, et al. Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels. J Biol Chem 2001;276:30701-30707
80. Phiel CJ, Wilson CA, lee VM, et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423:435-439
81. Koo EH, Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat Med 2004;10(Suppl):S26-33
82. Hu JH, Zhang H, Wagey R, et al. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 2003;85:432-442
83. Sugai F, Yamamoto Y, Miyaguchi K, et al. Benefit of valproic acid in suppressing disease progression of AlS model mice. Eur J Neurosci 2004;20:3179-3183
84. Endo H, Nito C, Kamada H, et al. Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 2006;26:1479-1489
85. Koh SH, Yoo AR, Chang DI, et al. Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions. Biochem Biophys Res Commun 2008;371:894-899
86. Romagnani P, lasagni l, Mazzinghi B, et al. Pharmacological modulation of stem cell function. Curr Med Chem 2007;14:1129-1139
87. Song l, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002;277:44701-44708
88. Duka T, Rusnak M, Drolet RE, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 2006;20:2302-2312
89. lee KY, Koh SH, Noh MY, et al. Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. Brain Res 2007;1129:89-99